title: HO-1 modified mesenchymal stem cells modulate MMPs/TIMPs system and adverse remodeling in infarcted myocardium.
abstract: The present study was to determine the effects of the heme oxygenase-1 (HO-1) modified mesenchymal stem cells (MSCs) transplantation into acute MI hearts on normalizing the ratio of MMPs/TIMPs and remodeling in infarcted myocardium. HO-1 was transfected into cultured MSCs using an adenoviral vector. 1 x 10(6) Ad-HO-1-transfected MSCs (HO-1-MSCs) or Ad-Null-transfected MSCs (Null-MSCs) or PBS was respectively injected into rat hearts 1 h intramyocardially after myocardial infarction. The cardiac performance was significantly improved and left ventricular dilatation was significantly attenuated in HO-1-MSCs transplanted hearts. Moreover, a significant increase in microvessel density was observed in HO-1-MSCs transplanted hearts. TIMP2,3 expression in HO-1-MSCs transplanted hearts was significantly increased, and MMP2,9 expression in HO-1-MSCs transplanted hearts was significantly lower than Null-MSCs transplanted and PBS-treated hearts. TIMP1 expression did not vary significantly. Null-MSCs transplantation did not decrease the expression of MMP2,9 significantly compared with PBS-treated hearts. The ratio of TIMP2 to MMP2, and TIMP3 to MMP9 in cell-grafted hearts was increased significantly. HO-1-MSCs transplantation normalize the ratio of MMPs/TIMPs, contributing to the reversion of myocardial extracellular remodeling.
authors.affiliation: Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China. zbch 1@163.com
authors.forename: Tao
authors.initials: T
authors.lastname: Shu
authors.forename: Bin
authors.initials: B
authors.lastname: Zeng
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Ren
authors.forename: Yanglin
authors.initials: Y
authors.lastname: Li
mesh_terms: D000818:Animals; D006334:Heart Function Tests; D051547:Heme Oxygenase-1 / Q000378:metabolism*; D006801:Humans; D008297:Male; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D009203:Myocardial Infarction / Q000201:enzymology / Q000503:physiopathology* / Q000628:therapy; D018919:Neovascularization, Physiologic; D010641:Phenotype; D051381:Rats; D017207:Rats, Sprague-Dawley; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*; D020257:Ventricular Remodeling / Q000502:physiology*
chemical_list: D019714:Tissue Inhibitor of Metalloproteinases; D051547:Heme Oxygenase-1; D020782:Matrix Metalloproteinases